Core Insights - Phathom Pharmaceuticals is set to present real-world data on its first-in-class treatment VOQUEZNA (vonoprazan) for gastroesophageal reflux disease (GERD) at Digestive Disease Week (DDW) from May 3-6, 2025, in San Diego, CA [1][3] - VOQUEZNA is the only treatment approved by the U.S. FDA for adults for heartburn relief associated with Non-Erosive GERD and for treating all severities of Erosive Esophagitis (Erosive GERD) [1][34] - The data presented will analyze treatment patterns and patient characteristics, indicating VOQUEZNA's potential role for patients inadequately managed by existing therapies [3] Company Activities - Two Phathom-sponsored posters will be presented on May 5, 2025, at the conference, along with a Product Theater highlighting VOQUEZNA [2] - The company will maintain a strong presence at the conference with a booth (1743) on the exhibit floor [2] Industry Context - GERD affects approximately 1 in 5 U.S. adults, with around 70% of the GERD population suffering from Non-Erosive GERD [31][32] - Erosive GERD, affecting about 30% of the GERD population, can lead to severe complications if inadequately treated [33] - The conference will showcase over 5,600 abstracts and hundreds of lectures on the latest advances in GI research, medicine, and technology [8]

Core Insights - Phathom Pharmaceuticals has appointed Ted Schroeder to its Board of Directors, which is seen as a strategic move during a critical time for the company [1][3]. Company Overview - Phathom Pharmaceuticals is focused on developing and commercializing novel treatments for gastrointestinal diseases, including the first-in-class potassium-competitive acid blocker (PCAB) vonoprazan, marketed as VOQUEZNA® [7]. Leadership Experience - Ted Schroeder brings over 30 years of experience in the biopharmaceutical industry, having held leadership roles in various companies and successfully guiding them through significant milestones and transactions [2][4]. - His previous roles include CEO of Nabriva Therapeutics and co-founder of Cadence Pharmaceuticals, which was acquired for $1.4 billion [4]. Strategic Importance - The appointment of Schroeder is expected to enhance Phathom's operational and commercial capabilities, particularly as the company aims to accelerate its commercial momentum and deliver innovative therapies to patients [3][5].

FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that Steven Basta has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Mr. Basta succeeds Terrie Curran, who is stepping down as President and CEO and as a member of the Board of Directors for personal reas ...

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2024 Earnings Conference Call March 6, 2025 8:30 AM ET Company Participants Eric Sciorilli - Head, Investor Relations Terrie Curran - President & Chief Executive Officer Martin Gilligan - Chief Commercial Officer Molly Henderson - Chief Financial Officer Conference Call Participants Yatin Suneja - Guggenheim Joseph Stringer - Needham Annabel Samimy - Stifel Kristen Kluska - Cantor Fitzgerald Paul Choi - Goldman Sachs Matthew Caufield - H.C. Wainwright Operator ...